Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDX NASDAQ:NTLA NASDAQ:RCKT NASDAQ:VIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$22.06-1.6%$20.87$14.40▼$47.00$1.49B1.13968,074 shs745,827 shsNTLAIntellia Therapeutics$12.63+4.7%$9.54$5.90▼$27.42$1.25B2.213.09 million shs6.75 million shsRCKTRocket Pharmaceuticals$3.13+3.0%$3.65$2.19▼$26.98$324.63M0.672.33 million shs2.82 million shsVIVOMeridian Bioscience$33.97$33.70$20.35▼$34.38$1.50B0.23973,737 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics0.00%-2.18%+9.32%+18.32%-39.04%NTLAIntellia Therapeutics0.00%+4.60%+31.09%+52.27%-51.91%RCKTRocket Pharmaceuticals0.00%+2.70%+12.59%-57.60%-86.68%VIVOMeridian Bioscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics2.1413 of 5 stars4.41.00.00.02.50.00.0NTLAIntellia Therapeutics4.3665 of 5 stars4.31.00.04.71.82.50.6RCKTRocket Pharmaceuticals4.8343 of 5 stars4.23.00.04.71.84.21.3VIVOMeridian BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.89Moderate Buy$50.11127.16% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37164.20% UpsideRCKTRocket Pharmaceuticals 2.41Hold$18.60494.25% UpsideVIVOMeridian Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTLA, RCKT, CLDX, and VIVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.006/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/13/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.006/3/2025RCKTRocket PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $11.005/30/2025RCKTRocket PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ In-Line$5.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/28/2025RCKTRocket PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025RCKTRocket PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.02M208.60N/AN/A$11.26 per share1.96NTLAIntellia Therapeutics$57.88M22.60N/AN/A$8.56 per share1.48RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/AVIVOMeridian Bioscience$333.02M4.49$1.78 per share19.13$8.41 per share4.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$157.86M-$2.70N/AN/AN/A-2,366.07%-23.46%-22.35%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)VIVOMeridian Bioscience$42.46M$0.9735.02∞N/A12.70%16.74%13.09%N/ALatest NTLA, RCKT, CLDX, and VIVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLDXCelldex Therapeutics-$0.86N/AN/AN/A$1.13 millionN/A8/14/2025Q2 2025NTLAIntellia Therapeutics-$1.03N/AN/AN/A$12.26 millionN/A8/4/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57N/AN/AN/A$4.36 millionN/A5/13/2025Q1 2025RCKTRocket Pharmaceuticals-$0.58-$0.56+$0.02N/AN/AN/A5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/5/2025Q1 2025RCKTRocket Pharmaceuticals-$0.59-$0.56+$0.03-$0.56$0.80 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/AVIVOMeridian BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A21.6721.67NTLAIntellia TherapeuticsN/A4.904.90RCKTRocket Pharmaceuticals0.059.199.19VIVOMeridian Bioscience0.073.632.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/ANTLAIntellia Therapeutics88.77%RCKTRocket Pharmaceuticals98.39%VIVOMeridian Bioscience89.72%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics4.40%NTLAIntellia Therapeutics3.10%RCKTRocket Pharmaceuticals24.76%VIVOMeridian Bioscience2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.46 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableRCKTRocket Pharmaceuticals240106.79 million80.35 millionOptionableVIVOMeridian Bioscience70244.01 million43.00 millionOptionableNTLA, RCKT, CLDX, and VIVO HeadlinesRecent News About These CompaniesMeridian Bioscience Introduces New Enzyme Stabilization Services for Molecular DiagnosticsApril 24, 2025 | finance.yahoo.comMeridian Bioscience Inc (VIVO)April 10, 2025 | uk.investing.comIndia's smartphone mkt grows 6%, Vivo topsNovember 13, 2024 | rediff.comRMeridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to SustainabilityNovember 7, 2024 | finance.yahoo.comMeridian Bioscience Gets $500K Top Prize in POC Blood Lead Test ChallengeOctober 28, 2024 | 360dx.com3Precision BioSciences Launches First Hepatitis B Gene-Editing TrialOctober 26, 2024 | precisionmedicineonline.comPWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comEditas strengthens in vivo gene therapy strategy via $238M LNP tech pact with GenevantOctober 22, 2024 | fiercebiotech.comFVivo and Arm collaborate on chip technology innovation, launch joint labOctober 21, 2024 | digitimes.comDvivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint LabOctober 18, 2024 | malaysiasun.comMMeridian Growth Legacy MERDXOctober 16, 2024 | morningstar.comMSerán Bioscience snags investment from Bain Capital Life SciencesSeptember 17, 2024 | pehub.comVivo T3 Ultra launch on September 12 – check what’s in store for India marketSeptember 6, 2024 | financialexpress.comFVivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comFast-growing MBX Biosciences raises another $63.5 million in fundingAugust 6, 2024 | ibj.comIMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comGrant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systemsMay 17, 2024 | bioworld.comBBiomerica, Inc. (BMRA)May 11, 2024 | finance.yahoo.comVivo X100s Pro with new Dimensity 9300 Plus chip could be launching soonMarch 24, 2024 | gizmochina.comGVivo V30 Pro review: Flagship-grade imaging system in a slender form factorMarch 13, 2024 | business-standard.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookBy Brian O'Connell | July 15, 2025View Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookNTLA, RCKT, CLDX, and VIVO Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$22.06 -0.35 (-1.56%) Closing price 04:00 PM EasternExtended Trading$22.08 +0.02 (+0.07%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Intellia Therapeutics NASDAQ:NTLA$12.63 +0.57 (+4.73%) Closing price 04:00 PM EasternExtended Trading$12.74 +0.11 (+0.87%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Rocket Pharmaceuticals NASDAQ:RCKT$3.13 +0.09 (+2.96%) Closing price 04:00 PM EasternExtended Trading$3.16 +0.04 (+1.12%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Meridian Bioscience NASDAQ:VIVOMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Domino’s Delivers Another Discounted Entry for Income Investors TSLA Earnings Week: Can Tesla Break Through $350? Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
